HK1186468A1 - 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms 4-[-2-[[5--1-(2-)-1h--3-]]] - Google Patents
4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms 4-[-2-[[5--1-(2-)-1h--3-]]]Info
- Publication number
- HK1186468A1 HK1186468A1 HK13113963.1A HK13113963A HK1186468A1 HK 1186468 A1 HK1186468 A1 HK 1186468A1 HK 13113963 A HK13113963 A HK 13113963A HK 1186468 A1 HK1186468 A1 HK 1186468A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- naphtalenyl
- pyrazol
- oxy
- ethyl
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10382225A EP2426111A1 (de) | 2010-08-09 | 2010-08-09 | Feste 4-[-2-[[5-Methyl-1-(2-naphthalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholinhydrochlorid-Formen |
PCT/EP2011/063583 WO2012019984A1 (en) | 2010-08-09 | 2011-08-08 | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1186468A1 true HK1186468A1 (en) | 2014-03-14 |
Family
ID=43244877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13113963.1A HK1186468A1 (en) | 2010-08-09 | 2013-12-16 | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms 4-[-2-[[5--1-(2-)-1h--3-]]] |
Country Status (19)
Country | Link |
---|---|
US (1) | US9428462B2 (de) |
EP (2) | EP2426111A1 (de) |
JP (1) | JP5899214B2 (de) |
KR (1) | KR20130095751A (de) |
CN (1) | CN103052626B (de) |
AR (1) | AR082608A1 (de) |
AU (1) | AU2011288550A1 (de) |
BR (1) | BR112013002651A2 (de) |
CA (1) | CA2807855C (de) |
CO (1) | CO6670586A2 (de) |
ES (1) | ES2543429T3 (de) |
HK (1) | HK1186468A1 (de) |
MA (1) | MA34512B1 (de) |
MX (1) | MX341711B (de) |
PT (1) | PT2603495E (de) |
RU (1) | RU2013110313A (de) |
SG (1) | SG187745A1 (de) |
TW (1) | TW201219387A (de) |
WO (1) | WO2012019984A1 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2116539A1 (de) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon |
EP2353591A1 (de) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Verstärkung der analgesischen Wirkung von Opioden und Opiaten bei postoperativem Schmerz und zur Schwächung der Abhängigkeit davon |
EP2353598A1 (de) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Anwendung in der Vorbeugung und/oder Behandlung von postoperativem Schmerz |
EP2388005A1 (de) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Vorbeugung und/oder Behandlung von Erbrechen infolge von Chemotherapie oder Strahlentherapie |
EP2415471A1 (de) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Verwendung von Sigmaliganden bei opioidinduzierter Hyperalgesie |
EP2524694A1 (de) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Verwendung von Sigmaliganden bei Schmerz im Zusammenhang mit Typ-2-Diabetes |
EP2792352A1 (de) | 2013-04-16 | 2014-10-22 | Laboratorios Del. Dr. Esteve, S.A. | Alpha-2-Adrenorezeptor und Sigmarezeptor-Ligande enthaltenden Kombinationen |
AU2014364644A1 (en) * | 2013-12-17 | 2016-06-23 | Laboratorios Del Dr. Esteve, S.A. | Gabapentinoids and Sigma receptor ligands combinations |
MA39147B1 (fr) | 2013-12-17 | 2019-12-31 | Esteve Labor Dr | Combinaisons d'inhibiteurs de la recapture de sérotonine-norépinéphrine (snri) et de ligands des récepteurs sigma |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04364129A (ja) | 1990-10-26 | 1992-12-16 | Asahi Chem Ind Co Ltd | 6−置換アルコキシキノキサリン誘導体含有医薬組成物およびその製造法 |
SE508669C2 (sv) | 1996-04-26 | 1998-10-26 | Astra Ab | Nytt förfarande |
EP2325174A1 (de) * | 2004-08-27 | 2011-05-25 | Laboratorios Del. Dr. Esteve, S.A. | Sigmarezeptor-Inhibitoren |
SI1781618T1 (sl) * | 2004-08-27 | 2013-01-31 | Laboratorios Del Dr. Esteve, S.A. | Inhibitorji sigma receptorja |
EP1634872A1 (de) * | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Pyrazolderivate als Inhibitoren von Sigmarezeptoren |
JPWO2009038112A1 (ja) | 2007-09-21 | 2011-01-06 | 塩野義製薬株式会社 | Npyy5受容体拮抗剤を含有する固形製剤 |
EP2116539A1 (de) * | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon |
EP2113501A1 (de) * | 2008-04-25 | 2009-11-04 | Laboratorios Del. Dr. Esteve, S.A. | 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazole als Sigma rezeptor-Hemmer |
EP2292236A1 (de) * | 2009-08-14 | 2011-03-09 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Vorbeugung oder Behandlung von Schmerzen infolge von Chemotherapie |
EP2361904A1 (de) | 2010-02-04 | 2011-08-31 | Laboratorios Del. Dr. Esteve, S.A. | 4-[-2-[[5-Methyl-1-(2-naphthalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholinhydrochlorid und kristalline Formen davon |
CN105859624A (zh) * | 2009-11-25 | 2016-08-17 | 埃斯特韦实验室有限公司 | 4- [2-[[5-甲基-1-(2-萘基)- 1h-吡唑-3-基]氧基]乙基]吗啉盐 |
EP2335688A1 (de) * | 2009-11-25 | 2011-06-22 | Laboratorios Del. Dr. Esteve, S.A. | Pharmazeutische Zusammensetzungen, die Sigmarezeptorliganden umfassen |
USRE47214E1 (en) * | 2010-02-04 | 2019-01-29 | Laboratorios Del Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates |
EP2426112A1 (de) | 2010-08-09 | 2012-03-07 | Laboratorios Del. Dr. Esteve, S.A. | 4-[-2-[[5-Methyl-1-(2-naphthalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholinhydrochloridpolymorphe und -solvate |
EP2353598A1 (de) * | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Anwendung in der Vorbeugung und/oder Behandlung von postoperativem Schmerz |
EP2388005A1 (de) * | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Vorbeugung und/oder Behandlung von Erbrechen infolge von Chemotherapie oder Strahlentherapie |
EP2415471A1 (de) * | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Verwendung von Sigmaliganden bei opioidinduzierter Hyperalgesie |
EP2460519A1 (de) * | 2010-12-03 | 2012-06-06 | Laboratorios Del. Dr. Esteve, S.A. | Verwendung von Sigmaliganden bei Knochenkrebsschmerz |
-
2010
- 2010-08-09 EP EP10382225A patent/EP2426111A1/de not_active Withdrawn
-
2011
- 2011-08-08 RU RU2013110313/04A patent/RU2013110313A/ru not_active Application Discontinuation
- 2011-08-08 SG SG2013009220A patent/SG187745A1/en unknown
- 2011-08-08 EP EP20110740675 patent/EP2603495B1/de active Active
- 2011-08-08 KR KR1020137006090A patent/KR20130095751A/ko not_active Application Discontinuation
- 2011-08-08 CA CA2807855A patent/CA2807855C/en not_active Expired - Fee Related
- 2011-08-08 AU AU2011288550A patent/AU2011288550A1/en not_active Abandoned
- 2011-08-08 MX MX2013001559A patent/MX341711B/es active IP Right Grant
- 2011-08-08 PT PT117406751T patent/PT2603495E/pt unknown
- 2011-08-08 CN CN201180038821.9A patent/CN103052626B/zh not_active Expired - Fee Related
- 2011-08-08 MA MA35713A patent/MA34512B1/fr unknown
- 2011-08-08 TW TW100128160A patent/TW201219387A/zh unknown
- 2011-08-08 JP JP2013523580A patent/JP5899214B2/ja not_active Expired - Fee Related
- 2011-08-08 BR BR112013002651A patent/BR112013002651A2/pt not_active Application Discontinuation
- 2011-08-08 WO PCT/EP2011/063583 patent/WO2012019984A1/en active Application Filing
- 2011-08-08 US US13/816,194 patent/US9428462B2/en not_active Expired - Fee Related
- 2011-08-08 ES ES11740675.1T patent/ES2543429T3/es active Active
- 2011-08-09 AR ARP110102890A patent/AR082608A1/es unknown
-
2013
- 2013-02-08 CO CO13026634A patent/CO6670586A2/es not_active Application Discontinuation
- 2013-12-16 HK HK13113963.1A patent/HK1186468A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2013110313A (ru) | 2014-09-20 |
SG187745A1 (en) | 2013-03-28 |
MX341711B (es) | 2016-08-31 |
WO2012019984A1 (en) | 2012-02-16 |
JP2013533298A (ja) | 2013-08-22 |
JP5899214B2 (ja) | 2016-04-06 |
PT2603495E (pt) | 2015-08-28 |
TW201219387A (en) | 2012-05-16 |
MA34512B1 (fr) | 2013-09-02 |
BR112013002651A2 (pt) | 2016-05-31 |
EP2603495B1 (de) | 2015-05-06 |
CA2807855C (en) | 2018-10-23 |
EP2426111A1 (de) | 2012-03-07 |
CN103052626A (zh) | 2013-04-17 |
CN103052626B (zh) | 2017-06-06 |
MX2013001559A (es) | 2013-03-07 |
ES2543429T3 (es) | 2015-08-19 |
US9428462B2 (en) | 2016-08-30 |
KR20130095751A (ko) | 2013-08-28 |
US20130150575A1 (en) | 2013-06-13 |
AU2011288550A1 (en) | 2013-02-21 |
CA2807855A1 (en) | 2012-02-16 |
CO6670586A2 (es) | 2013-05-15 |
AR082608A1 (es) | 2012-12-19 |
EP2603495A1 (de) | 2013-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1186468A1 (en) | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms 4-[-2-[[5--1-(2-)-1h--3-]]] | |
HK1179477A1 (en) | Kinase inhibitors | |
IL221277A0 (en) | 4 - [- 2 - [[5 - methyl- 1 - (2 - naphtalenyl) - 1h - pyrazol - 3 - yl] oxy ] ethyl] morpholine hydrochloride polymorphs and solvates | |
ZA201203842B (en) | Kinase inhibitors | |
IL211863A0 (en) | Reduced size self-delivering rnai compounds | |
EP2402918A4 (de) | Einrichtung zum sortieren und bindeverarbeitung von banknoten | |
EP2558099A4 (de) | Kinase-inhibitoren | |
IL219997A0 (en) | 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts | |
EP2501681A4 (de) | Zwitterionenhaltige acridinverbindungen | |
IL214293A0 (en) | Dihydroquinolinone derivatives | |
IL214251A0 (en) | Isoxazole derivatives | |
EP2480076A4 (de) | Imidothiazolkinaseinhibitoren | |
HK1201759A1 (en) | 4-methylpyrazole formulations 4- | |
ZA201107435B (en) | Pyrazole copmpound | |
EP2449565A4 (de) | Zündspule | |
PL2400960T3 (pl) | Metabolity będące analogami ceramidowymi | |
PL2646448T3 (pl) | Makrocykliczne inhibitory kinazy | |
HK1178522A1 (en) | Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents | |
IL220307A (en) | Secondary history of 8-hydroxyquinoline-7-carboxamide | |
GB0914726D0 (en) | Kinase inhibitors | |
AU4436P (en) | Selexion Valerianella locusta | |
GB2470588B (en) | Drawing aid | |
AU2009901386A0 (en) | Coil arrangement | |
AU2009901941A0 (en) | Adjustable insert | |
AU2009905324A0 (en) | Golf Improvement Aid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190814 |